Open the filing on EDGARFulgent Reports Third Quarter 2026 Financial Results
Revenue of $90.4 million, growing approximately 8% year-over-year
GAAP gross profit of $31.9 million, or GAAP gross margin of 35.3%; Non-GAAP gross profit of $32.8 million, or Non-GAAP gross margin of 36.3%
GAAP loss of $13.2 million, or $(0.48) per share; Non-GAAP loss of $2.4 million, or $(0.09) per share
Ended the third quarter of 2026 with $652.4 million of cash, cash equivalents, restricted cash, and investments in marketable securities
Maintains annual revenue guidance of $330.0-$340.0 million
Improves outlook for annual Non-GAAP loss and cash guidance, as a result of disciplined spend across the business
EL MONTE, CA, November 5, 2026 - Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026.
Third Quarter 2026 Results:
Revenue of $90.4 million
GAAP loss of $13.2 million, or $(0.48) per share
Non-GAAP loss of $2.4 million, or $(0.09) per share
Adjusted EBITDA loss of $7.5 million
Non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), GAAP gross profit and margin, and GAAP operating income (loss) and margin, in the accompanying tables.
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Paul Kim, Chief Financial Officer, said, “We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
Outlook:
For the full year 2026, Fulgent expects:
Revenue to be in the range of $330.0-$340.0 million
For the full year 2026, Fulgent now expects:
Non-GAAP loss of approximately $46.0-$50.0 million
Non-GAAP loss of approximately $1.65-$1.75 per share, which includes the impact of a reduction of 4.1 million shares used for the stock repurchase program, year to date as of September 30, 2026
Cash, cash equivalents, restricted cash, and investments in marketable securities of approximately $630.0 million, which includes $64.1 million of cash used for the stock repurchase program, year to date as of September 30, 2026*
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program, or other expenditures outside the ordinary course of business, including M&A. This number assumes capital purchases of $13 million, no further near-term repurchases under the stock repurchase program, and spend on the therapeutic development business of $21 million. The timing and amount of any future repurchases pursuant to the stock repurchase program will depend on a variety of factors, including the market price of Fulgent’s common stock, general market and economic conditions, and other factors Fulgent’s board of directors may deem relevant.
Conference Call Information
Fulgent will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter 2026 results. The call may be accessed through a live audio webcast in the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
Note Regarding Non-GAAP Financial Measures
Certain information set forth in this press release and/or to be discussed on the Company’s earnings call, including non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are non-GAAP financial measures. Fulgent believes this information is useful to investors because it provides a basis for measuring the performance of the Company’s business, excluding certain income or expense items that management believes are not directly attributable to the Company’s operating results. Fulgent defines non-GAAP income (loss) as net income (loss) calculated in accordance with accounting principles generally accepted in the United States of America, or GAAP, plus amortization of intangible assets, plus impairment loss, plus equity-based compensation expenses, plus acquisition-related costs, which include one-time banker fees, legal, valuation, due diligence, and closing costs, plus acquisition-related severance, plus or minus the non-GAAP tax effect, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. The non-GAAP tax effect was calculated by excluding from the GAAP provision the impact of the amortization of intangible assets, impairment loss, equity-based compensation expenses, acquisition-related costs, and acquisition-related severance. Fulgent defines adjusted EBITDA income (loss) as GAAP income (loss) plus or minus interest (expense) income, plus or minus provisions (benefits) for income taxes, plus depreciation and amortization, plus equity-based compensation expenses, plus insurance expense related to transferable tax credits, plus impairment loss, plus acquisition-related costs, plus acquisition-related severance, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. Fulgent defines non-GAAP gross profit as gross profit calculated in accordance with GAAP plus equity-based compensation included in cost of revenue as shown in the table below.
Fulgent defines non-GAAP gross margin by taking non-GAAP gross profit and dividing it by GAAP revenue. Fulgent defines non-GAAP operating profit (loss) by taking GAAP operating profit (loss) and adding equity-based compensation expense, amortization of intangible assets, impairment of intangible assets, acquisition-related costs, and acquisition-related severance. Non-GAAP operating margin is calculated by taking non-GAAP operating profit (loss) and dividing it by GAAP revenue. Fulgent may continue to incur expenses similar to the items added to or subtracted from the GAAP financial measures, and, accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure in evaluating the Company’s operating performance and for internal planning and budgeting. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies. The Company does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because the information necessary to calculate such reconciliations is unavailable on a forward‑looking basis without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amounts of items that would be included in the GAAP measures, including, but not limited to, equity‑based compensation, tax effects, acquisition‑related items, and potential impairments, any of which could be material. The Company is also unable to predict the probable significance of such items.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Forward-Looking Statements
Forward-looking statements notice
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward‑looking statements are often identified by words such as “anticipate”, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “project,” “should,” “target,” “will,” and similar expressions. Examples of forward-looking statements in this press release include statements about, among other things: future performance; guidance, including guidance regarding expected quarterly and annual financial results, revenue, GAAP loss, non-GAAP loss and related per share figures, and cash, cash equivalents, restricted cash, and investments in marketable securities; potential improvements in margins; evaluations and judgments regarding the strength of the Company’s business; the potential benefits of the continued integration of AI into the Company’s laboratory business and expansion of the Company’s AI portfolio; any references (express or implied) to the potential benefits of the StrataDx and Bako Diagnostics acquisitions, including any potential or expected revenue and whether the revenue will offset loss of other revenues; the Company’s ability to remediate operational issues relating to the transition of its billing and revenue cycle management systems; the Company’s continued and future research and development efforts, including any implications that the results of earlier clinical trials will be representative of, or consistent with later clinical trials; and the Company’s identification and evaluation of opportunities and its ability to capitalize on opportunities, capture market share, or expand its presence in certain markets; and the Company’s ability to continue to grow its business.
Forward-looking statements notice
Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the Company’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on the Company’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others, risks regarding: the market potential for, and the rate and degree of market adoption of, the Company’s tests; its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the Company’s ability to maintain the low internal costs of its business model; the Company’s ability to maintain an acceptable margin; risks related to volatility in the Company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the Company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the Company’s revenue; dependence on a limited number of customers, including risks that any such customer may further reduce, delay, or internalize testing volumes; risks related to the Company’s acquisitions, including Bako and StrataDx, such as integration challenges, costs, and the Company’s ability to realize expected benefits on anticipated timelines; the Company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests and testing services, including its ability to manage and to remediate billing software implementation issues and claims processing delays; the Company’s level of success in establishing and obtaining the intended benefits from partnerships, strategic investments, joint ventures, acquisitions, or other relationships; the success of the Company’s development efforts, including the Company’s ability to progress its candidates through clinical trials on the timelines expected; the outcome of the Company’s interactions with the FDA and other regulators, including whether FDA feedback on the Company’s proposed Phase 3 trial of FID-007 will require changes to the trial design that delay its commencement or increase its cost; the Company’s ability to successfully develop, validate, and deploy artificial intelligence applications in its laboratory operations, including the risk that such applications may not perform in clinical use as they have in internal testing, and evolving laws and regulations applicable to the use of artificial intelligence in diagnostic testing; the Company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; the Company’s ability to obtain expected tax refunds on the timelines expected; and the Company’s ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.
The forward-looking statements made in this press release speak only as of the date of this press release, and the Company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
The Company’s reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on the Company’s website and on the SEC’s website at www.sec.gov upon their filing with the SEC. These reports contain more information about the Company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release.
| September 30, 2026 | December 31, 2025 |
|---|
| FULGENT GENETICS, INC. | | |
| Condensed Consolidated Balance Sheet Data |
| September 30, 2026, and December 31, 2025 |
| (in thousands) | | |
| ASSETS: | | |
| Cash and cash equivalents | $86,787 | $50,193 |
| Investments in marketable securities | 565,502 | 655,153 |
| Accounts receivable, net | 62,494 | 84,762 |
| Property, plant, and equipment, net | 110,738 | 112,549 |
| Other assets | 253,408 | 310,868 |
| Total assets | $1,078,929 | $1,213,525 |
| LIABILITIES & EQUITY: | | |
| Accounts payable, accrued liabilities and other liabilities | $94,221 | $106,810 |
| Total stockholders’ equity | 984,708 | 1,106,715 |
| Total liabilities & equity | $1,078,929 | $1,213,525 |
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2026 | 2025 | 2026 | 2025 |
|---|
| FULGENT GENETICS, INC. | | | | |
| Condensed Consolidated Statement of Operations Data |
| Three and Nine Months Ended September 30, 2026, and 2025 |
| (in thousands, except per share data) |
| (unaudited) |
| Revenue | $90,412 | $84,069 | $246,939 | $239,335 |
| Cost of revenue (1) | 58,465 | 48,557 | 167,823 | 141,042 |
| Gross profit | 31,947 | 35,512 | 79,116 | 98,293 |
| Operating expenses | | | | |
| Research and development (1) | 13,636 | 13,860 | 42,366 | 39,735 |
| Selling and marketing (1) | 15,606 | 11,642 | 43,055 | 32,393 |
| General and administrative (1) | 22,761 | 23,335 | 77,640 | 75,018 |
| Amortization of intangible assets | 2,491 | 2,025 | 7,125 | 6,005 |
| Impairment of intangible assets | - | - | 2,172 | - |
| Total operating expenses | 54,494 | 50,862 | 172,358 | 153,151 |
| Operating loss | (22,547) | (15,350) | (93,242) | (54,858) |
| Interest income | 8,554 | 7,874 | 23,609 | 23,983 |
| Interest expense | (7) | (28) | (83) | (59) |
| Impairment of equity securities | - | - | - | (9,926) |
| Other (expense) income, net | (43) | (5) | 5 | 109 |
| Total other income, net | 8,504 | 7,841 | 23,531 | 14,107 |
| Loss before income taxes | (14,043) | (7,509) | (69,711) | (40,751) |
| Benefit from income taxes | (704) | (683) | (1,379) | (2,770) |
| Net loss from consolidated operations | (13,339) | (6,826) | (68,332) | (37,981) |
| Net loss attributable to noncontrolling interests | 187 | 218 | 824 | 886 |
| Net loss attributable to Fulgent | $(13,152) | $(6,608) | $(67,508) | $(37,095) |
| Net loss per common share attributable to Fulgent: | | | | |
| Basic | $(0.48) | $(0.21) | $(2.34) | $(1.21) |
| Diluted | $(0.48) | $(0.21) | $(2.34) | $(1.21) |
| Weighted-average common shares: | | | | |
| Basic | 27,662 | 30,749 | 28,837 | 30,708 |
| Diluted | 27,662 | 30,749 | 28,837 | 30,708 |
| (1) Equity-based compensation expense was allocated as follows: | | | | |
| Cost of revenue | $885 | $1,697 | $3,431 | $5,214 |
| Research and development | 2,953 | 3,247 | 9,626 | 10,060 |
| Selling and marketing | 536 | 736 | 1,746 | 2,337 |
| General and administrative | 3,746 | 4,037 | 11,831 | 12,695 |
| Total equity-based compensation expense | $8,120 | $9,717 | $26,634 | $30,306 |
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2026 | 2025 | 2026 | 2025 |
|---|
| FULGENT GENETICS, INC. | | | | |
| Non-GAAP Income (Loss) Reconciliation |
| Three and Nine Months Ended September 30, 2026, and 2025 |
| (in thousands, except per share data) |
| Net loss attributable to Fulgent | $(13,152) | $(6,608) | $(67,508) | $(37,095) |
| Amortization of intangible assets | 2,491 | 2,025 | 7,125 | 6,005 |
| Impairment loss (1) | - | - | 2,172 | 9,926 |
| Equity-based compensation expense | 8,120 | 9,717 | 26,634 | 30,306 |
| Acquisition-related costs (2) | - | 90 | 2,649 | 387 |
| Acquisition-related severance (3) | - | - | 647 | - |
| Non-GAAP tax effect | 134 | (703) | (1,269) | (1,466) |
| Non-GAAP (loss) income attributable to Fulgent | $(2,407) | $4,521 | $(29,550) | $8,063 |
| Net loss per common share attributable to Fulgent: | | | | |
| Basic | $(0.48) | $(0.21) | $(2.34) | $(1.21) |
| Diluted | $(0.48) | $(0.21) | $(2.34) | $(1.21) |
| Non-GAAP (loss) income per common share attributable to Fulgent: | | | | |
| Basic | $(0.09) | $0.15 | $(1.02) | $0.26 |
| Diluted | $(0.09) | $0.14 | $(1.02) | $0.26 |
| Weighted average common shares: | | | | |
| Basic | 27,662 | 30,749 | 28,837 | 30,708 |
| Diluted | 27,662 | 31,312 | 28,837 | 30,952 |
(1) Consists of non-cash charges related to (i) a 2026 impairment of an intangible asset previously acquired through a business combination and (ii) a 2025 impairment of a prior investment.
(2) Consists of acquisition-related costs related to the acquisitions of Bako and StrataDx for the nine months ended September 30, 2026.
(3) Consists of one-time severance payments to the former CEO & CFO of Bako and StrataDx for the nine months ended September 30, 2026.
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2026 | | 2025 | | 2026 | | 2025 | |
|---|
| FULGENT GENETICS, INC. | | | | |
| Non-GAAP Adjusted EBITDA Reconciliation |
| Three and Nine Months Ended September 30, 2026, and 2025 |
| (in thousands) | | | | |
| Net loss attributable to Fulgent | | $(13,152) | | $(6,608) | | $(67,508) | | $(37,095) |
| Interest income, net | | (8,547) | | (7,846) | | (23,526) | | (23,924) |
| Benefit from income taxes | | (704) | | (683) | | (1,379) | | (2,770) |
| Depreciation and amortization | | 6,816 | | 6,038 | | 20,492 | | 18,011 |
| Equity-based compensation expense | | 8,120 | | 9,717 | | 26,634 | | 30,306 |
| Insurance expense related to transferable tax credits | | - | | - | | - | | 283 |
| Impairment loss | | - | | - | | 2,172 | | 9,926 |
| Acquisition-related costs | | - | | 90 | | 2,649 | | 387 |
| Acquisition-related severance | | - | | - | | 647 | | - |
| Adjusted EBITDA | | $(7,467) | | $708 | | $(39,819) | | $(4,876) |
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2026 | 2025 | 2026 | 2025 |
|---|
| FULGENT GENETICS, INC. | | | | |
| Non-GAAP Operating Margin |
| Three and Nine Months Ended September 30, 2026, and 2025 |
| (in thousands, except percentages) | | | | |
| Revenue | $90,412 | $84,069 | $246,939 | $239,335 |
| Cost of revenue | 58,465 | 48,557 | 167,823 | 141,042 |
| Gross profit | 31,947 | 35,512 | 79,116 | 98,293 |
| Gross margin | 35.3% | 42.2% | 32.0% | 41.1% |
| Equity-based compensation included in cost of revenue | 885 | 1,697 | 3,431 | 5,214 |
| Non-GAAP gross profit | 32,832 | 37,209 | 82,547 | 103,507 |
| Non-GAAP gross margin | 36.3% | 44.3% | 33.4% | 43.2% |
| Operating expenses | 54,494 | 50,862 | 172,358 | 153,151 |
| Operating loss | (22,547) | (15,350) | (93,242) | (54,858) |
| Operating margin | -24.9% | -18.3% | -37.8% | -22.9% |
| Equity-based compensation included in operating expenses | 7,235 | 8,020 | 23,203 | 25,092 |
| Amortization of intangible assets | 2,491 | 2,025 | 7,125 | 6,005 |
| Impairment of intangible assets | - | - | 2,172 | - |
| Acquisition-related costs | - | 90 | 2,649 | 387 |
| Acquisition-related severance | - | - | 647 | - |
| Non-GAAP operating expenses | 44,768 | 40,727 | 136,562 | 121,667 |
| Non-GAAP operating loss | $(11,936) | $(3,518) | $(54,015) | $(18,160) |
| Non-GAAP operating margin | -13.2% | -4.2% | -21.9% | -7.6% |
Contacts
The Blueshirt Group
Lauren Sloane, lauren@blueshirtgroup.com